Homologous recombination deficiency (HRD) status is widely used to guide treatment decisions in advanced ovarian cancer, particularly in the context of PARP inhibitors. However, real-world evidence suggests that HRD classification may not fully capture the biological heterogeneity underlying treatment response. We aimed to evaluate the concordance between HRD status and clinical outcomes in a contemporary cohort.
Monge et al. (Wed,) studied this question.